<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        250-334-17
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2017
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        LEVONIC 5 mg/ml Infusion
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        LEVOFLOXACIN
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        5
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg/ml
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Intravenous use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Solution for infusion
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        50
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        1
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Bag
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Generic
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        24
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        35.65
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="Hikma Pharmaceuticals PLC" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            Hikma Pharmaceuticals PLC
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 441]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Jazeera Pharmaceutical Industries (JPI)
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            Jazeera Pharmaceutical Industries (JPI)
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        J01MA12
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>What type of medicine is Levonic solution?</strong></p><p>Levofloxacin, the active ingredient of the solution for infusion, is a synthetic antibacterial agent of the fluoroquinolone class (antibiotic) for administration into a vein.</p><p><strong>Why has Levonic infusion been prescribed?</strong></p><p>The solution for infusion is indicated for the treatment of the following bacterial infections when caused by sensitive micro-organisms:</p><ul><li>&nbsp; &nbsp; &nbsp; Community acquired pneumonia</li><li>&nbsp; &nbsp; &nbsp; &nbsp;Complicated (difficult to treat) urinary tract infections including pyelonephritis (infection of the kidney)</li><li>&nbsp; &nbsp; &nbsp; Skin and soft tissue infections</li><li>&nbsp; &nbsp; &nbsp; &nbsp;Infection of the prostate</li></ul>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>When you should not use Levonic infusion?</strong></p><p>You should not be administered the infusion if you have ever had an allergic reaction to levofloxacin or any other quinolone antibiotic.Otherwise you could have a similar reaction to Levonic.</p><p>You should not be administered the infusion if you suffer from epilepsy. Otherwise, your risk of getting &ldquo;fits&rdquo; (convulsions) is increased.</p><p>You should not be administered the infusion if you have ever had tendon problems (e.g. tendinitis) related to treatment with an antibiotic of the fluoroquinolone class.This is because there is a risk of getting similar problems with Levonic, including tendon rupture.</p><p>The infusion is only intended for adults and must not be given to children or growing teenagers.</p><p><strong>Pregnancy and Breastfeeding</strong></p><p>You should not be administered the infusion if you are pregnant or breast-feeding a baby.</p><p>Levonic could harm your baby.</p><p>The infusion is only intended for adults and must not be given to children or growing teenagers. It could harm the cartilage of their growing bones.</p><p>Tell your doctor if you have had any problems with medicines in the past.</p><p><strong>What special precautions should be taken?</strong></p><p>The risk of getting &ldquo;fits&rdquo; may be increased if in the past you have experienced brain damage (such as stroke or severe brain injury) and are now treated with Levonic. (You should not be administered the infusion if you suffer from epilepsy).</p><p>Make sure your doctor knows about your medical history, so he can give you appropriate advice. The risk of getting &ldquo;fits&rdquo; may also be increased if you take Levonic with certain other drugs (with fenbufen or similar medicines against rheumatic pain and inflammation, or with theophylline). Probenecid and cimetidine reduce your kidneys ability to get rid of your medicine, this is unlikely to have any clinical relevance.</p><p>Your medicine may also prolong the effect of ciclosporin. The infusion lead to an increase in bleeding in patients taking Vitamin K anatagonists, such as warfarin.</p><p>This medicinal product contains sodium. To be taken into consideration by patients on a controlled sodium diet.</p><p>Tell your doctor about <strong>all </strong>medicines you are taking including any that you bought without a prescription, as some of them could have an interaction with Levonic. Furthermore, do not take any new medicine without consulting your doctor.</p><p>Infusion Time</p><p>The recommended infusion time of at least 30 minutes for 250 mg or 60 minutes for 500 mg Levonic solution for infusion should be observed. It is known for ofloxacin, that during infusion tachycardia and a temporary decrease in blood pressure may develop. In rare cases, as a consequence of a profound drop in blood pressure, circulatory collapse may occur.</p><p>Should a conspicuous drop in blood pressure occur during infusion of levofloxacin, (l-isomer of ofloxacin) the infusion must be halted immediately.</p><p>Do not stay out in strong sunlight for unnecessarily long periods and do not use a sun-lamp or solarium while you are taking Levonic. This is because some patients may become more sensitive to light whilst receiving the infusion (sunburn-like reactions).</p><p>Tell your doctor immediately if you have severe, persistent and/or bloody diarrhoea during or after treatment with the infusion. This may be a sign of a serious bowel inflammation (pseudomembranous colitis) which may occur following treatment by antibiotics, and it may be necessary to stop treatment and start specific therapy.</p><p>Levonic may, in rare cases, cause pain and inflammation in tendons, particularly in elderly patients or in patients taking corticosteroids (cortisone and similar medicines). If you experience any tendon complaints whilst or shortly after receiving the infusion, seek medical advice immediately and rest the affected limb to avoid tendon damage. It may be necessary to stop treatment.</p><p>Patients with some abnormality of an enzyme called glucose-6-phosphate dehydrogenase (G6- PD) (a rare hereditary disease) may beprone to destruction of red blood cells (hemolysis) when treated with quinolone antibacterial agents, and so levofloxacin should be used with caution in these patients.</p><p><strong>Tell your doctor before taking Levonic:</strong></p><ul><li>&nbsp; &nbsp; &nbsp; &nbsp;If you have been diagnosed with an enlargement or &quot;bulge&quot; of a large blood vessel (aortic aneurysm or large vessel peripheral aneurysm).</li><li>&nbsp; &nbsp; &nbsp; If you have experienced a previous episode of aortic dissection (a tear in the aorta wall).</li><li>&nbsp; &nbsp; &nbsp;If you have a family history of aortic aneurysm or aortic dissection or other risk factors or predisposing conditions (e.g. connective tissue disorders such as Marfan syndrome, or vascular Ehlers-Danlos syndrome, or vascular disorders such as Takayasu arteritis, giant cell arteritis, Behcet&rsquo;s disease, high blood pressure, or known atherosclerosis).</li><li>&nbsp; &nbsp; &nbsp; &nbsp;If you feel sudden, severe pain in your abdomen, chest or back, go immediately to an emergency room.</li></ul><p><strong>What special precautions should be taken when driving a car or operating machinery?</strong></p><p>Some side-effects like dizziness, drowsiness, visual disturbances, may impair your ability to concentrate and react. Do not drive, operate dangerous machinery or have similar activities if you feel that your ability to concentrate and react is impaired.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Dosage</strong></p><p>The dose of levofloxacin is determined by the type and severity of the infection.</p><p>Your doctor or nurse will decide how to give your medicine.</p><p><strong>Dosage in patients with normal kidney function</strong></p><p>(creatinine clearance above 50 ml/min):</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td><p><strong>Indication</strong></p></td><td><p><strong>Daily dose regimen</strong></p><p>(according to severity)</p></td></tr><tr><td><p>Prostatitis</p></td><td><p>500 mg once daily</p></td></tr><tr><td><p>Community acquired</p><p>pneumonia</p></td><td><p>500 mg once or twice</p><p>daily</p></td></tr><tr><td><p>Complicated urinary</p><p>tract infections including pyelonephritis</p></td><td><p>250 mg<sup>1</sup> once daily</p></td></tr><tr><td><p>Skin and soft tissue</p><p>infections</p></td><td><p>500 mg twice daily</p></td></tr></tbody></table><p><sup>1</sup> consideration should be given to increasing the dose in cases of severe infection</p><p><strong>Elderly patients and patients with impaired liver function </strong>(but normal kidney function) should receive the same dosage as normal adult.</p><p>Much of the information that follows is intended for your doctor or nurse.</p><p><strong>Dosage in patients with renal insufficiency</strong></p><p>(creatinine clearance &le; 50 ml/min):</p><p>If your renal function is below normal your doctor will reduce the dose of Levonic as shown below.</p><p><strong>Dose regimen</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td><p>&nbsp;</p></td><td><p><strong>250 mg/24 h</strong></p></td><td><p><strong>500 mg/24 h</strong></p></td><td><p><strong>500 mg/12 h</strong></p></td></tr><tr><td><p><strong>Creatinine</strong></p><p><strong>clearance</strong></p></td><td><p><strong>first dose</strong></p><p><strong>250 mg</strong></p></td><td><p><strong>first dose</strong></p><p><strong>500 mg</strong></p></td><td><p><strong>first dose</strong></p><p><strong>500 mg</strong></p></td></tr><tr><td><p>50-20 ml/min</p></td><td><p>then:</p><p><strong>125</strong>mg/<strong>24</strong>h</p></td><td><p>then:</p><p><strong>250</strong>mg/<strong>24</strong>h</p></td><td><p>then:</p><p><strong>250</strong>mg/<strong>12</strong>h</p></td></tr><tr><td><p>19-20 ml/min</p></td><td><p>then:</p><p><strong>125</strong>mg/<strong>48</strong>h</p></td><td><p>then:</p><p><strong>125</strong>mg/<strong>24</strong>h</p></td><td><p>then:</p><p><strong>125</strong>mg/<strong>12</strong>h</p></td></tr><tr><td><p>&lt; 10 ml/min (including hemo- dialysis and</p><p>GAPD)<sup>1</sup></p></td><td><p>then:</p><p><strong>125</strong>mg/<strong>48</strong>h</p></td><td><p>then:</p><p><strong>125</strong>mg/<strong>24</strong>h</p></td><td><p>then:</p><p><strong>125</strong>mg/<strong>24</strong>h</p></td></tr></tbody></table><p><sup>1</sup>No additional doses are required after hemodialysis or continuous ambulatory peritoneal dialysis (CAPD).</p><p><strong>Administration</strong></p><p>The solution for infusion is ready for use, and should only be administered by <strong>slow </strong>infusion into a vein.The infusion time should <strong>not </strong>be <strong>less than 30 minutes </strong>(1/2 hour) for 250 mg (50 ml) or <strong>not </strong>be <strong>less than 60 minutes </strong>(1 hour) for 500 mg (100 ml) Levonic solution for infusion (See precautions for use). Protection from light is not necessary during infusion time (see How to store this medicine). For incompatibilities/ compatibilities see How to store and handle this medicine.</p><p><strong>Duration of treatment</strong></p><p>The duration of treatment is determined according to your clinical condition and your response to treatment. As with all antibacterial agents, treatment with Levonic <strong>&nbsp;</strong>(infusion solution or tablets) should be continued for at least 2 to 3 days after body temperature has returned to normal and the symptoms have subsided.</p><p>Once your condition has improved, the way your treatment is given may be changed from&nbsp; an infusion into a vein to tablets given orally at the same daily dose.</p><p><strong>If you take more Levonic</strong><strong>&nbsp;&nbsp;than you should</strong></p><p>Your doctor or nurse will ensure that you will receive the correct dose into the vein.</p><p>An accidental overdose might result in central nervous system symptoms such as confusion, dizziness, impairment of consciousness, and (convulsive) fits and heart disorders, possibly leading to abnormal heart rhythm.</p><p>In the event of overdose treatment is according to symptoms.</p><p>Levofloxacin is not removed from the body by dialysis. No specific antidote exists.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>What side effects may occur?</strong></p><p>The side-effects in this section are given with an estimation of the frequency with which they may occur. For this purpose the following frequency categories and denominations have been used:</p><p>Common: side-effects which may occur in 1 to 10 out of 100 patients.</p><p>Uncommon: side-effects which may occur in less than 1 out of 100 patients.</p><p>Rare: side-effects which may occur in less than 1 out of 1000 patients.</p><p>Very rare: side-effects which may occur in less than 1 out of 10 000 patients.</p><p>Isolated cases: even more rare.</p><p><strong>General allergic reactions, skin reactions</strong></p><p>Uncommon: itching and rash.</p><p>Rare: general allergic reactions (anaphylactic/ anaphylactoid reactions) (which may sometimes occur even with the first dose and which may develop during infusion or fast within minutes or hours of infusion) with symptoms such as wheals (urticaria), cramping of the bronchi and possibly severe breathing problems, as well as in very rare cases swelling of the skin and mucous membranes (e.g. in the face and throat).</p><p>Very rare: sudden drop in blood pressure or collapse (shock). Such general allergic reactions may sometimes be preceded by e.g. mild skin reactions.</p><p>Increased sensitivity of the skin to sun and ultraviolet light may also occur.</p><p>Isolated cases: severe blistering reactions of the skin and mucous membranes (Steven&rsquo;s Johnson syndrome), toxic epidermal necrolysis (Lyell syndrome) and erythema exsudativum multiforme.</p><p><strong>Gastro-intestinal, metabolism</strong></p><p>Common: nausea, vomiting, diarrhoea</p><p>Uncommon: loss of appetite, stomach upset (dyspepsia), or pain in the abdominal region.</p><p>Rare: bloody diarrhoea which in very rare cases may be indicative of enterocolitis (inflammation of the bowel), including pseudomembranous colitis.</p><p>Very rare: fall of blood sugar to a too low level (hypoglycaemia) which may be of special importance in patients treated for diabetes.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Your doctor or nurse will ensure that Levonic is properly stored. As with all medicines it must be kept out of the reach of children.</p><p>Store below 30&deg;C</p><p>This medicine should be kept in its foil wrap for protection from light until use. No protection from light is required during the injection, or within three days after removal from the outer packaging if stored under indoor light conditions.</p><p>Once the infusion bag has been opened the solution should be used immediately (within 3 hours) in order to prevent any bacterial contamination.</p><p>This medicine should not be mixed with alkaline solutions (e.g. sodium bicarbonate) or with heparin.</p><p>This medicine may be given alone or with one of the following solutions:</p><p>0.9% sodium chloride solution</p><p>5% dextrose injection</p><p>2.5% dextrose in Ringer solution</p><p>combination solutions for parenteral nutrition (amino acids, carbohydrates, electrolytes).</p><p>Do not use this medicine after the expiry date shown on the packaging.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Each bottle of Levonic solution for infusion contains levofloxacin (5 mg/ml) as active ingredient.</p><p>Levonic solution for infusion is available in bottles of 50 ml (250 mg) and 100 ml (500 mg).</p><p>The solution also contains the following ingredients sodium chloride; sodium hydroxide; hydrochloric acid and water for injection.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                50 or 100 ml of ready for use solution, which is greenish-yellow in colour. It is provided in either a 50 or 100 ml polypropylene bags.
Levonic 250 mg/50 ml in 50 ml Bags (1 Bag)
Levonic 500 mg/100 ml in 100 ml Bags (1 Bag)

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Marketing Authorization Holder</strong></p><p>Jazeera Pharmaceutical Industries</p><p>Al-Kharj Road P.O.BOX 106229</p><p>Riyadh, 11666, Saudi Arabia</p><p>Tel: 00 (966-11) 4980170</p><p>Fax: 00 (966-11) 4980187</p><p><strong>Manufacturer</strong></p><p>Hikma Farmaceutica</p><p>Estrada do Rio Da M&oacute;, n.&deg;8, 8A e 8B</p><p>Ferven&ccedil;a</p><p>Sintra, Portugal</p><p>Tel. 00351219608410</p><p>Fax 00351219615102</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                This leaflet was last approved in 02/2014; version number 1.2.
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL"><strong>ما هي نوعية دواء محلول ليفونيك ؟</strong></p><p dir="RTL">المادة الفعالة في هذه المحلول هي الليفوفلوكساسين. وهي ينتمي إلى مجموعة من الأدوية المعروفة باسم المضادات الحيوية الفلوروكينولون التي تقتل البكتيريا للاستخدام من خلال التسريب الوريدي .</p><p dir="RTL"><strong>استخدامات محلول ليفونيك</strong></p><p dir="RTL">تستخدم محلول <strong>ليفونك </strong>لعلاج الالتهابات البكتيرية التالية والتي تسببها البكتيريا التي تعتبر حساسة لليفوفلوكساسين.</p><ul dir="rtl"><li>التهاب الرئتين المكتسب من المجتمع</li><li>التهابات المسالك البولية المصحوبة بمضاعفات ، بما في ذلك &nbsp;التهاب الكليتين .</li><li>التهابات الجلد والانسجة الرخوة .</li><li>التهاب غدة البروستات.</li></ul>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>متى يتوجب عليك عدم استخدام محلول ليفونك</strong><strong> :</strong></p><ul dir="rtl"><li>إذا كنت شديدة الحساسية تجاه ليفوفلوكساسين أو أي من المكونات الأخرى التي تنتمي لمجموعة المضادات الحيوية (كينولون) او اي مكونات اخرى لهذا الدواء .</li><li>إذا كنت تعاني من الصرع. خلاف ذلك، هناك احتمال زيادة خطر الاصابة &quot;بالنوبات &quot; (التشنجات).</li><li>إذا كنت قد اصبت بالماضي بمشاكل في الاوتار (مثل التهاب الأوتار التهاب الأوتار ) المرتبطة بالمعالجة بمادة فعالة تنتمي إلى نفس الفئة&nbsp; من المضادات الحيوية (أي الفلوروكينولونات). وذلك لأن هناك خطر من الحصول على مشاكل مماثلة مع ليفونك ، بما في ذلك تمزق في وتر.</li></ul><p dir="RTL">يتوجب استخدام التسريب الوريدي فقط للبالغين ويجب ألا تعطى للأطفال أو المراهقين.</p><p dir="RTL"><strong>الحمل والرضاعة</strong></p><p dir="RTL">يجب الامتناع عن استخدام هذا المحلول للتسريب الوريدي :</p><ul dir="rtl"><li>إذا كنت حامل أو تخططين لتصبحي حاملا أو انك ترضعين حاليا رضاعة طبيعية.</li></ul><p dir="RTL">قد يضر <strong>ليفونك </strong>طفلك.</p><p dir="RTL">أخبر طبيبك عن أي مشاكل ناتجة عن تناول الأدوية في الماضي.</p><p dir="RTL"><strong>تحذيرات خاصة اثناء تناول محلول ليفونك</strong><strong>:</strong></p><p dir="RTL">يمكن ان يزداد خطر الإصابة &quot; بالنوبات التشنجية &quot; إذا تعرضت سابقا لتلف في الدماغ ( مثل السكتة الدماغية أو إصابة شديدة في الدماغ ) وتستخدم الان دواء <strong>ليفونك </strong>(يتوجب عدم استخدام ليفونك عن الطريق التسريب الوريدي إذا كنت تعاني من الصرع ).</p><p dir="RTL">تأكد ان الطبيب يعرف التاريخ المرضي السابق لك حتى يتسنى له اعطائك المشورة الصحيحة . يتزايد خطر النوبات التشنجية ايضا اذا استخدمت دواء <strong>ليفونك </strong>مع بعض الادوية الأخرى (مع فينبوفين أو أدوية مماثلة تستخدم ضد آلام الروماتيزم والالتهاب ، أو مع الثيوفيلين ) . البروبينسيد و السيميتيدين يحد من قدرة كليتيك للتخلص من الادوية ومن المرجح أن يكون لهذا أهمية سريرية .</p><p dir="RTL">قد يطيل هذا الدواء أيضا تأثير السيكلوسبورين . يؤدي التسريب إلى زيادة النزيف في المرضى الذين يتناولون مضادات فيتامين &nbsp;k &nbsp;، مثل الوارفارين .</p><p dir="RTL">يحتوي هذا الدواء على الصوديوم. لذا ينصح بأخذ هذا بعين الاعتبار لدى الاشخاص الذين يتبعون حمية مضبوطة بالصوديوم.</p><p dir="RTL">أخبر طبيبك عن جميع الأدوية التي تتناولها بما في ذلك أي ادوية تم شراؤها من دون وصفة طبية،حيث ان بعضها يمكن أن يتفاعل مع <strong>ليفونك </strong>وعلاوة على ذلك ، لا تستعمل أي دواء جديد دون استشارة الطبيب.</p><p dir="RTL">الوقت اللازم للتسريب يجب ان لا يقل عن 30 دقيقة لجرعة 250 ملغ أو 60 دقيقة لجرعة 500 ملغ لحقن <strong>محلول ليفونيك</strong>.</p><p dir="RTL">ومن المعروف انه اثناء اعطاء أوفلوكساسين بالمحلول الوريدي يمكن ان تظهر اعراض عدم انتظام دقات القلب و انخفاض مؤقت في ضغط الدم. في حالات نادرة ،ونتيجة للانخفاض الكبير في ضغط الدم ، قد يحدث انهيار في الدورة الدموية.</p><p dir="RTL">اذا نشات علامات على انخفاض واضح في ضغط الدم خلال ضخ الليفوفلوكساسين ، (أيزومرمن أوفلوكساسين) يجب وقف التسريب فورا.</p><p dir="RTL">لا تتعرض لاشعة الشمس القوية لفترات طويلة ولا يتستخدم مصباح الشمس أو الاستلقاء تحت أشعة الشمس اثناء استخدم <strong>ليفونيك </strong>. لأن بعض المرضى قد يصبحوا أكثر حساسية تجاة الضوء اثناء تلقي التسريب (حروق الشمس مثلا).</p><p dir="RTL">أخبر طبيبك فورا إذا كان لديك استمرار شديد للاسهال و / أو اسهال دموي أثناء أو بعد العلاج مع الحقن في الوريد.</p><p dir="RTL">قد يكون ذلك ناتج عن التهاب شديد في الأمعاء (التهاب القولون الغشائي الكاذب) التي قد تحدث بعد العلاج بواسطة المضادات الحيوية ، وأنه قد يكون من الضروري وقف العلاج و بدء علاج اخر.</p><p dir="RTL">قد يسبب <strong>ليفونيك </strong>في حالات نادرة ، الألم والالتهاب في الأوتار ، وخاصة في المرضى كبار السن أو في المرضى الذين يتناولون الكورتيكوستيرويد ( الكورتيزون والأدوية المماثلة) . إذا اشتكيت أي من اعراض في الاوتار بعد فترة وجيزة من استخدام التسريب، استشر طبيبك فورا وارح الطرف المصاب لتجنب الضرر للوتر . قد يكون من الضروري وقف العلاج.</p><p dir="RTL">المرضى الذين يعانون من بعض الاختلالات في انزيم الجلوكوز 6 فوسفات ديهيدروجينيز ( مرض وراثي نادر ) قد يكونوا عرضة لتلف خلايا الدم الحمراء ( انحلال الدم)&nbsp; عندما استخدام الادوية المصنعة من الكينولون والمضاد ة للجراثيم ، و لذلك ينبغي أن تستخدم الليفوفلوكساسين بحذر لهؤلاء المرضى.</p><p dir="RTL"><strong>أخبر طبيبك قبل تناول ليفونك</strong><strong>:</strong></p><ul dir="rtl"><li>إذا تم تشخيصك بتضخم أو &quot;انتفاخ&quot; في الأوعية الدموية الكبيرة (تمدد الوعاء الدموي الأبهري أو تمدد الوعاء الدموي الكبير المحيطي).</li><li>إذا كنت قد تعرضت سابقا لتشريح الأبهر (تمزق في الجدار الأبهري).</li><li>إذا كان لديك تاريخ عائلي من تمدد الوعاء الدموي الأبهري أو تشريح الأبهر أو لديك عوامل خطر أخرى أو حالات مهيّئة (مثل اضطرابات النسيج الضام مثل: متلازمة مارفان، أو متلازمة إِهلرز دانلوس الوعائية، أواضطرابات وعائية مثل شريان تكاياسو، شريان ذو الخلايا العملاقة، متلازمة بهجت، ارتفاع ضغط الدم، أو تصلب معروف في الشرايين).</li><li>إذا شعرت بألم شديد، مفاجئ في البطن، الصدر أو الظهر، اذهب على الفور إلى غرفة الطوارئ.</li></ul><p dir="RTL"><strong>ما هي الاحتياطات الخاصة الواجب اتخاذها عند قيادة السيارة أو تشغيل الآلات </strong>؟</p><p dir="RTL">قد تؤدي بعض الآثار الجانبية مثل الدوخة ، النعاس ،والاضطرابات البصرية, قد يؤدي الى ضعف قدرتك على التركيز والاستجابة . لا تقد المركبات او تشغل الالات إذا كنت تشعر أن قدرتك على التركيز والاستجابة ضعيفة .</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">الجرعة :</p><p dir="RTL">تعتمد فترة العلاج على نوع وشدة الالتهاب.</p><p dir="RTL">سيقوم الطبيب أو الممرض بوصف الجرعات المحددة ومدة تناول هذه المحلول.</p><p dir="RTL">الجرعة في المرضى الذين لديهم وظيفة الكلى طبيعية( طرح الكرياتينين اعلى من 50 مل/د )</p><table dir="rtl" border="1" cellspacing="0" cellpadding="0" style="width:636px"><tbody><tr><td style="vertical-align:top"><p dir="RTL">دواعي الاستعمال</p></td><td style="vertical-align:top"><p dir="RTL">جدول الجرعة اليومية</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">التهاب البروستات</p></td><td style="vertical-align:top"><p dir="RTL">500 مجم مرة واحدة يوميا</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">التهاب الرئة المكتسب من المجتمع</p></td><td style="vertical-align:top"><p dir="RTL">500 مجم مرة واحدة &nbsp;أو مرتين يوميا</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">التهاب المسالك البولية المصحوب بمضاعفات بما فيها التهاب الحويضة والكلية</p></td><td style="vertical-align:top"><p dir="RTL"><sup>1</sup>250 مجم مرة واحدة يوميا</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">التهابات الجلد والانسجة الرخوة</p></td><td style="vertical-align:top"><p dir="RTL">500 مجم مرتين يوميا</p></td></tr></tbody></table><p dir="RTL"><sup>1</sup>يجب الانتباه لزيادة الجرعة في حال الالتهاب الشديد. &nbsp;المسنين والمرضى الذين يعانون من ضعف وظائف الكبد (ولكن وظيفة الكلى طبيعية) ينبغي أن يتلقوا نفس الجرعة كالكبار.</p><p dir="RTL">الكثير من المعلومات التالية موجهة لطبيبك أو الممرضة.</p><p dir="RTL">الجرعة في حالات المرضى الذين يعانون من القصور الكلوي (طرح الكرياتينين اقل من 50 مل / دقيقة ):</p><p dir="RTL">إذا كانت وظيفة الكلى اقل من المعتاد سيقوم طبيبك بتقليل جرعة <strong>ليفونيك </strong>كما هو مبين أدناه.</p><p dir="RTL"><strong>جدول الجرعات</strong></p><table dir="rtl" border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p dir="RTL">&nbsp;</p></td><td style="vertical-align:top"><p dir="RTL">&nbsp; &nbsp;250 ملغم/ 24 س</p></td><td style="vertical-align:top"><p dir="RTL">500 ملغم/ 24 س</p></td><td style="vertical-align:top"><p dir="RTL">500 ملغم/ 12 س</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">طرح الكرياتينين</p></td><td style="vertical-align:top"><p dir="RTL">الجرعة 1</p><p dir="RTL">250 ملغم</p></td><td style="vertical-align:top"><p dir="RTL">الجرعة 1</p><p dir="RTL">500 ملغم</p></td><td style="vertical-align:top"><p dir="RTL">الجرعة 1</p><p dir="RTL">500 ملغم</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">50 &ndash; 20 مل/د</p></td><td style="vertical-align:top"><p dir="RTL">ثم 125 ملغم/ 24 س</p></td><td style="vertical-align:top"><p dir="RTL">ثم 250 ملغم/ 24 س</p></td><td style="vertical-align:top"><p dir="RTL">ثم 125 ملغم/ 12 س</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">19 -20 &nbsp;مل/د</p></td><td style="vertical-align:top"><p dir="RTL">ثم 125 ملغم/ 48 س</p></td><td style="vertical-align:top"><p dir="RTL">ثم 125 ملغم/ 24 س</p></td><td style="vertical-align:top"><p dir="RTL">ثم 125 ملغم/ 12 س</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">أقل من 10 مل/د بما فيه غسيل الكلى</p></td><td style="vertical-align:top"><p dir="RTL">ثم 125 ملغم/ 48 س</p></td><td style="vertical-align:top"><p dir="RTL">ثم 125 ملغم/ 24 س</p></td><td style="vertical-align:top"><p dir="RTL">ثم 125 ملغم/ 12 س</p></td></tr></tbody></table><p dir="RTL">لا يوجد حاجة لجرعات اضافية بعد غسيل الكلى او استمرار الغسيل البريتوني.</p><p dir="RTL"><strong>طريقة الاستعمال</strong></p><p dir="RTL">عندما يصبح المحلول جاهزا للاستخدام ينبغي أن يستخدم فقط عن طريق التسريب البطيء في الوريد. لا ينبغي أن تكون مدة التسريب أقل من 30 دقيقة (1 / 2 ساعة) لجرعة 250 ملغ( 50 ) &nbsp;مل أو ليس أقل من 60 دقيقة (1 ساعة&nbsp; ) لجرعة500 ملغ ( 100 مل ) من محلول ليفونيك &nbsp;( انظر احتياطات الاستخدام ) . ليس من الضروري الحماية من الضوء خلال فترة التسريب (انظر كيفية تخزين والتعامل مع هذا الدواء ) . لعدم التوافق / التوافق انظر كيفية التخزين والتعامل مع هذا الدواء.</p><p dir="RTL"><strong>مدة العلاج</strong></p><p dir="RTL">يتم تحديد مدة العلاج وفقا للحالتك السريرية والاستجابة للعلاج. كما هو الحال مع جميع الادوية المضادة للبكتيريا يجب استمرار العلاج بدواء ليفونيك (محلول التسريب أو الاقراص ) لمدة2 إلى 3 ايام على الأقل بعد عودة درجة حرارة الجسم الى الدرجة الطبيعية واختفاء الأعراض. عند تحسن حالتك، قد يتم تغيير طريقة العلاج من التسريب في الوريد الى الاقراص عن طريق الفم بنفس الجرعة اليومية.</p><p dir="RTL"><strong>إذا تناولت جرعة أكثر من اللازم من ليفونك</strong></p><p dir="RTL">سيقوم الطبيب او الممرض من التاكد من تلقيك للجرعة الصحيحة في الوريد. تشمل علامات فرط الجرعة الغيرر مقصودة اعراض تؤثر على الجهاز العصبي المركزي مثل التشوش، والدوخة، وضعف الوعي والنوبات ( التشنجية ) واضطراب ضربات القلب، مما قد يؤدي إلى ضربات غير طبيعية للقلب.</p><p dir="RTL">ويتم معالجة هذه المشكلة حسب الاعراض. لا يتم ازالة اليفوفلوكاساسين عن طريق غسيل الكلى . ولا يوجد ترياق خاص لذلك.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">يتم تقييم الاثار الجانبية في هذا البند حسب معدل وتكرار حدوث هذه الاثار. لهذا الغرض يتم استخدام الفئات</p><p dir="RTL">والتقسيمات التالية:</p><p dir="RTL">شائع: الآثار الجانبية التي تحدث في 1 <strong>- </strong>10 من أصل 100 مريض.</p><p dir="RTL">غير شائعة: الآثار الجانبية التي تحدث في أقل من 1 من أصل 100 مريض.</p><p dir="RTL">نادرة : من الآثار الجانبية التي تحدث في أقل من 1 من أصل1000 مريض .</p><p dir="RTL">نادرة جدا : الآثار الجانبية التي تحدث في أقل من 1 من أصل 10000 مريض .</p><p dir="RTL">حالات معزولة: أكثر ندرة.</p><p dir="RTL"><strong>ردود فعل تحسسية عامة، ردود فعل جلدية</strong></p><p dir="RTL">شائعة: الحكة والطفح الجلدي.</p><p dir="RTL">نادرة: الحساسية العامة (تحسسية / ردود الفعل شبه تحسسية (تحدث في بعض الأحيان مع الجرعة الأولى و التي قد تتطور خلال التسريب أو تتسارع خلال دقائق أو ساعات من التسريب) مع أعراض مثل الحكة التحسسية (الشرى )، تشنج الشعب الهوائية واحتمال نشوء مشاكل حادة في التنفس وربما في حالات نادرة جدا تورم الجلد والأغشية المخاطية (مثل في الوجه و الحلق )&nbsp;.</p><p dir="RTL">نادرة جدا: انخفاض مفاجئ في ضغط الدم أو انهيار (صدمة ). قد تظهر اعراض الحساسية العامة هذه في بعض الأحيان مسبوقة بأعراض جلدية خفيفة قد تحدث أيضا زيادة حساسية الجلد لأشعة الشمس والأشعة فوق البنفسجية</p><p dir="RTL">حالات معزولة: تفاعلات شديدة في الجلد والأغشية المخاطية (متلازمة ستيفن جونسون)، انحلال البشرة السمي (متلازمة لييل) والحمامي متعدد الاشكال.</p><p dir="RTL"><strong>اعراض في المعدة والأمعاء، والتمثيل الغذائي</strong></p><p dir="RTL">الشائعة: الغثيان، التقيؤ والإسهال.</p><p dir="RTL">غير شائعة: فقدان الشهية، واضطراب في المعدة (عسر الهضم)، أو ألم في البطن.</p><p dir="RTL">نادرة: الإسهال المصحوب بدم الذي في حالات نادرة جدا قد تكون مؤشرا على حالات التهاب الأمعاء بما في ذلك التهاب القولون الكاذب.</p><p dir="RTL">نادرة جدا: هبوط نسبة السكر في الدم إلى مستوى منخفض للغاية والتي قد تكون ذات أهمية خاصة في المرضى المصابين بالسكري.</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">سيقوم الطبيب أو الممرضة بالتأكد من أن ليفونيك مخزن بشكل صحيح. كما هو الحال مع جميع الأدوية يجب أبقاء هذا<strong> </strong>الدواء بعيدا عن متناول الأطفال.</p><p dir="RTL">يحفظ هذا المستحضر تحت 30 &deg; مئوية.</p><p dir="RTL">يجب أن يبقى هذا الدواء مغطى بقصدير للحماية من الضوء حتى موعد الاستخدام. لا حاجة للحماية من الضوء أثناء الحقن، أو خلال ثلاثة أيام بعد اخراجه من العبوة الخارجية إذا خزن تحت ظروف الإضاءة الداخلية.</p><p dir="RTL">عند فتح زجاجة التسريب (سدادة مطاطية مثقوبة) ينبغي استخدام المحلول على الفور (خلال 3 ساعات) وذلك لمنع حدوث أي تلوث جرثومي.</p><p dir="RTL">لا ينبغي خلط هذا الدواء مع محاليل أخرى (مثل كربونات الصوديوم) أو مع الهيبارين.</p><p dir="RTL">يمكن إعطاء هذا الدواء وحده أو مع واحد من المحاليل التالية:</p><p dir="RTL">0.9 ٪ محلول كلوريد الصوديوم.</p><p dir="RTL">5 ٪ محلول دكستروز .</p><p dir="RTL">2.5 ٪ محلول دكستروز في محلول رينغر .</p><p dir="RTL">محاليل مختلطة للتغذية الوريدية (الأحماض الأمينية والكربوهيدرات و الكراهل )</p><p dir="RTL">لا تستخدم هذا الدواء بعد انتهاء تاريخه المبين على العبوة.</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">&nbsp;</p><p dir="RTL">تحتوي كل زجاجة من محلول ليفونيك للتسريب على الليفوفلوكساسين ( 5 ملغ / مل) كمكون نشط.</p><p dir="RTL">محلول ليفونيك للتسريب متوفر في زجاجات من 50 مل ( 250 ملغ) و 100 مل ( 500 ملغ). يتضمن المحلول أيضا</p><p dir="RTL">المكونات التالية كلوريد الصوديوم و هيدروكسيد الصوديوم و حمض الهيدروكلوريك و ماء للحقن.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">50 &nbsp;أو 100 مل محلول جاهز للاستخدام لونه اصفر مخضر.</p><p dir="RTL">ويتم تجهيزه في قوارير زجاجية حجم 50 أو 100 مل مع سدادة مطاطية.</p><p dir="RTL">ليفونيك 250 مغ/ 50 مل في كيس (50 مل)</p><p dir="RTL">ليفونيك 500 مغ/ 100 مل في كيس (&nbsp;100 مل)</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الشركة المالكة لحق التسويق</strong></p><p dir="RTL">شركة الجزيرة للصناعات الدوائية</p><p dir="RTL">الرياض 11666 ، ص.ب: 106229</p><p dir="RTL">ايميل: <u>medical@jpi.com.sa</u></p><p dir="RTL">المملكة العربية السعودية</p><p dir="RTL"><strong>الشركة المصنعة</strong></p><p dir="RTL">الحكمة للصناعات للدوائية (البرتغال) س.أ</p><p dir="RTL">فيرفنسا</p><p dir="RTL">البرتغال</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            تم اقرار هذه النشرة بتاريخ 02 / 2014 رقم النسخة 1.2
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Levonic 250 mg Bag
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Each 50 ml bag contains 250 mg Levofloxacin. 
For the full list of excipients, see section 6.1
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Clear green to yellow solution free from particles.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Levonic solution for infusion is indicated in adults for the treatment of the following infections (see sections 4.4 and 5.1):</p><ul><li>Community-acquired pneumonia</li><li>Complicated skin and soft tissue infections</li></ul><p>For the above-mentioned infections Levonic should be used only when it is considered inappropriate to use antibacterial agents that are commonly recommended for the initial treatment of these infections.</p><ul><li>Pyelonephritis and complicated urinary tract infections (see section 4.4)</li><li>Chronic bacterial prostatitis</li><li>Inhalation Anthrax: postexposure prophylaxis and curative treatment (see section 4.4)</li><li>Consideration should be given to official guidance on the appropriate use of antibacterial agents.</li></ul>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Levonic solution for infusion is administered by slow intravenous infusion once or twice daily. The dosage depends on the type and severity of the infection and the susceptibility of the presumed causative pathogen. Treatment with Levonic after initial use of the intravenous preparation may be completed with an appropriate oral presentation according to the SPC for the film-coated tablets and as considered appropriate for the individual patient. Given the bioequivalence of the parenteral and oral forms, the same dosage can be used.</p><p>The following dose recommendations can be given for Levonic:</p><p><strong>Dosage in patients with normal renal function (creatinine clearance &gt; 50 ml/min)&nbsp;</strong></p><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td><p><strong>Indication</strong></p></td><td><p><strong>Daily dose</strong></p><p><strong>regimen </strong>(according to severity)</p><p>&nbsp;</p></td><td><p><strong>Total duration of treatment1</strong>(according to severity)</p></td></tr><tr><td><p>Community-acquired pneumonia</p></td><td><p>500 mg once or twice daily</p></td><td><p>7 &ndash; 14 days</p></td></tr><tr><td><p>Pyelonephritis</p></td><td><p>500mg once daily</p></td><td><p>7 &ndash; 10 days</p></td></tr><tr><td><p>Complicated urinary tract infections</p></td><td><p>500mg once daily</p></td><td><p>7-14 days</p></td></tr><tr><td><p>Chronic bacterial prostatitis</p></td><td><p>500mg once daily</p></td><td><p>28 days</p></td></tr><tr><td><p>Complicated skin and soft tissue infections</p></td><td><p>500 mg once or twice daily</p></td><td><p>7 &ndash; 14 days</p></td></tr><tr><td><p>Inhalation anthrax</p></td><td><p>500mg once daily</p></td><td><p>8 weeks</p></td></tr></tbody></table><p>Treatment duration includes intravenous plus oral treatment. The time to switch from intravenous to oral treatment depends on the clinical situation but is normally 2 to 4 days.</p><ul><li>Special populations</li></ul><p>- Impaired renal function (creatinine clearance &le; 50 ml/min)</p><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td><p>&nbsp;</p></td><td><p><strong>Dose regimen</strong></p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td></tr><tr><td><p>&nbsp;</p></td><td><p>&nbsp;</p><p><strong>250 mg/24 h</strong></p><p>&nbsp;</p></td><td><p><strong>500 mg/24 h</strong></p></td><td><p><strong>500 mg/12 h</strong></p></td></tr><tr><td><p><strong>Creatinine clearance</strong></p></td><td><p>first dose: 250 mg</p></td><td><p>first dose: 500 mg</p></td><td><p>first dose: 500 mg</p></td></tr><tr><td><p>50 - 20 ml/min</p></td><td><p>then: 125 mg/24 h</p></td><td><p>then: 250 mg/24 h</p></td><td><p>then : 250 mg/12 h</p></td></tr><tr><td><p>19-10 ml/min</p></td><td><p>then: 125 mg/48 h</p></td><td><p>then: 125 mg/24 h</p></td><td><p>then: 125 mg/12 h</p></td></tr><tr><td><p>&lt; 10 ml/min (including haemodialysis and CAPD)<sup>1</sup></p></td><td><p>then: 125 mg/48 h</p></td><td><p>then: 125 mg/24 h</p></td><td><p>then: 125 mg/24 h</p></td></tr></tbody></table><p>(1) No additional doses are required after haemodialysis or continuous ambulatory peritoneal dialysis (CAPD).</p><p>- Impaired liver function</p><p>No adjustment of dose is required since levofloxacin is not metabolised to any relevant extent by the liver and is mainly excreted by the kidneys.</p><p>- Elderly population</p><p>No adjustment of dose is required in the elderly, other than that imposed by consideration of renal function (see section 4.4 &ldquo;Tendinitis and tendon rupture&rdquo; and &ldquo;QT interval prolongation&rdquo;).</p><p>- Paediatric population</p><p>Levonic is contraindicated in children and growing adolescents (see section 4.3).</p><ul><li>&nbsp;Method of administration</li></ul><p>Levonic solution for infusion is only intended for slow intravenous infusion; it is administered once or twice daily. The infusion time must be at least 30 minutes for 250 mg or 60 minutes for 500 mg Levonic solution for infusion (see section 4.4).</p><p>For incompatibilities see section 6.2 and compatibility with other infusion solutions see section 6.6.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Levofloxacin solution for infusion must not be used:
-	in patients hypersensitive to levofloxacin or any other quinolone and any of the excipients listed in section 6.1,
-       in patients with epilepsy,
-	in patients with history of tendon disorders related to fluoroquinolone administration,
-	in children or growing adolescents,
-       during pregnancy ,
-       in breast-feeding women .
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Methicillin-resistant S. aureus are very likely to possess co-resistance to fluoroquinolones, including levofloxacin. Therefore levofloxacin is not recommended for the treatment of known or suspected MRSA infections unless laboratory results have confirmed susceptibility of the organism to levofloxacin (and commonly recommended antibacterial agents for the treatment of MRSA-infections are considered inappropriate). Resistance to fluoroquinolones of E. coli &ndash; the most common pathogen involved in urinary tract infections &ndash; varies across the European Union. Prescribers are advised to take into account the local prevalence of resistance in E. coli to fluoroquinolones.</p><p>Inhalation Anthrax: Use in humans is based on in vitro Bacillus anthracis susceptibility data and on animal experimental data together with limited human data. Treating physicians should refer to national and/or international consensus documents regarding the treatment of anthrax.</p><ul><li>Infusion Time</li></ul><p>The recommended infusion time of at least 30 minutes for 250 mg or 60 minutes for 500 mg Levonic solution for infusion should be observed. It is known for ofloxacin that during infusion tachycardia and a temporary decrease in blood pressure may develop. In rare cases, as a consequence of a profound drop in blood pressure, circulatory collapse may occur. Should a conspicuous drop in blood pressure occur during infusion of levofloxacin, (l-isomer of ofloxacin) the infusion must be halted immediately.</p><ul><li>Sodium content</li></ul><p>This medicinal product contains sodium per. To be taken into consideration by patients on a controlled sodium diet.</p><ul><li>Tendinitis and tendon rupture</li></ul><p>Tendinitis may rarely occur. It most frequently involves the Achilles tendon and may lead to tendon rupture. Tendinitis and tendon rupture, sometimes bilateral, may occur within 48 hours of starting treatment with levofloxacin and have been reported up to several months after discontinuation of treatment. The risk of tendinitis and tendon rupture is increased in patients aged over 60 years, in patients receiving daily doses of 1000 mg and in patients using corticosteroids. The daily dose should be adjusted in elderly patients based on creatinine clearance (see section 4.2). Close monitoring of these patients is therefore necessary if they are prescribed levofloxacin. All patients should consult their physician if they experience symptoms of tendinitis. If tendinitis is suspected, treatment with levofloxacin must be halted immediately, and appropriate treatment (e.g. immobilisation) must be initiated for the affected tendon (see sections 4.3 and 4.8).</p><ul><li>Clostridium difficile-associated disease</li></ul><p>Diarrhoea, particularly if severe, persistent and/or bloody, during or after treatment with levofloxacin (including several weeks after treatment), may be symptomatic of Clostridium difficile-associated disease (CDAD). CDAD may range in severity from mild to life threatening, the most severe form of which is pseudomembranous colitis (see section 4.8). It is therefore important to consider this diagnosis in patients who develop serious diarrhoea during or after treatment with levofloxacin. If CDAD is suspected or confirmed, levofloxacin should be stopped immediately and appropriate treatment initiated without delay. Anti-peristaltic medicinal products are contraindicated in this clinical situation.</p><ul><li>Patients predisposed to seizures</li></ul><p>Quinolones may lower the seizure threshold and may trigger seizures. Levofloxacin is contraindicated in patients with a history of epilepsy (see section 4.3) and, as with other quinolones, should be used with extreme caution in patients predisposed to seizures or concomitant treatment with active substances thatlower the cerebral seizure threshold, such as theophylline (see section 4.5). In case of convulsive seizures (see section 4.8), treatment with levofloxacin should be discontinued.</p><ul><li>Patients with G-6- phosphate dehydrogenase deficiency</li></ul><p>Patients with latent or actual defects in glucose-6-phosphate dehydrogenase activity may be prone to haemolytic reactions when treated with quinolone antibacterial agents. Therefore, if levofloxacin has to be used in these patients, potential occurrence of haemolysis should be monitored.</p><ul><li>&nbsp; Patients with renal impairment</li></ul><p>Since levofloxacin is excreted mainly by the kidneys, the dose of Levonic should be adjusted in patients with renal impairment (see section 4.2).</p><ul><li>Hypersensitivity reactions</li></ul><p>Levofloxacin can cause serious, potentially fatal hypersensitivity reactions (e.g. angioedema up to anaphylactic shock), occasionally following the initial dose (see section 4.8). Patients should discontinue treatment immediately and contact their physician or an emergency physician, who will initiate appropriate emergency measures.</p><ul><li>Severe bullous reactions</li></ul><p>Cases of severe bullous skin reactions such as Stevens-Johnson syndrome or toxic epidermal necrolysis have been reported with levofloxacin (see section 4.8). Patients should be advised to contact their doctor immediately prior to continuing treatment is skin and/or mucosal reactions occur.</p><ul><li>Dysglycaemia</li></ul><p>As with all quinolones, disturbances in blood glucose, including both hypoglycaemia and hyperglycaemia have been reported, usually in diabetic patients receiving concomitant treatment with an oral hypoglycaemic agent (e.g., glibenclamide) or with insulin. Cases of hypoglycaemic coma have been reported. In diabetic patients, careful monitoring of blood glucose is recommended (see section 4.8).</p><ul><li>Prevention of photosensitisation</li></ul><p>Photosensitisation has been reported with levofloxacin (see section 4.8). It is recommended that patients should not expose themselves unnecessarily to strong sunlight or to artificial UV rays (e.g. sunray lamp, solarium), during treatment and for 48 hours following treatment discontinuation in order to prevent photosensitisation.</p><ul><li>Patients treated with Vitamin K antagonists</li></ul><p>Due to possible increase in coagulation tests (PT/INR) and/or bleeding in patients treated with levofloxacin in combination with a vitamin K antagonist (e.g. warfarin), coagulation tests should be monitored when these drugs are given concomitantly (see section 4.5).</p><ul><li>Psychotic reactions</li></ul><p>Psychotic reactions have been reported in patients receiving quinolones, including levofloxacin. In very rare cases these have progressed to suicidal thoughts and self-endangering behaviour- sometimes after only a single dose of levofloxacin (see section 4.8). In the event that the patient develops these reactions, levofloxacin should be discontinued and appropriate measures instituted. Caution is recommended if levofloxacin is to be used in psychotic patients or in patients with history of psychiatric disease.</p><ul><li>QT interval prolongation</li></ul><p>Caution should be taken when using fluoroquinolones, including levofloxacin, in patients with known risk factors for prolongation of the QT interval such as, for example:</p><p>&middot;&nbsp; congenital long QT syndrome</p><p>&middot;&nbsp; concomitant use of drugs that are known to prolong the QT interval (e.g. Class IA and III antiarrhythmics, tricyclic antidepressants, macrolides, antipsychotics).</p><p>&middot;&nbsp; uncorrected electrolyte imbalance (e.g. hypokalemia, hypomagnesemia)</p><p>&middot;&nbsp; cardiac disease (e.g. heart failure, myocardial infarction, bradycardia)</p><p>Elderly patients and women may be more sensitive to QTc-prolonging medications. Therefore, caution should be taken when using fluoroquinolones, including levofloxacin, in these populations. (see sections 4.2 Elderly, 4.5, 4.8, and 4.9).</p><ul><li>Peripheral neuropathy</li></ul><p>Peripheral sensory neuropathy and peripheral sensory motor neuropathy have been reported in patients receiving fluoroquinolones, including levofloxacin, which can be rapid in its onset (see section 4.8). Levofloxacin should be discontinued if the patient experiences symptoms of neuropathy in order to prevent the development of an irreversible condition.</p><ul><li>Hepatobiliary disorders</li></ul><p>Cases of hepatic necrosis up to fatal hepatic failure have been reported with levofloxacin, primarily in patients with severe underlying diseases, e.g. sepsis (see section 4.8). Patients should be advised to stop treatment and contact their doctor if signs and symptoms of hepatic disease develop such as anorexia, jaundice, dark urine, pruritus or tender abdomen.</p><ul><li>Exacerbation of myasthenia gravis</li></ul><p>Fluoroquinolones, including levofloxacin, have neuromuscular blocking activity and may exacerbate muscle weakness in patients with myasthenia gravis. Postmarketing serious adverse reactions, including deaths and the requirements for respiratory support, have been associated with fluoroquinolone use in patients with myasthenia gravis. Levofloxacin is not recommended in patients with a known history of myasthenia gravis.</p><ul><li>Vision disorders</li></ul><p>If vision becomes impaired or any effects on the eyes are experienced, an eye specialist should be consulted immediately (see sections 4.7 and 4.8).</p><p>-&nbsp;&nbsp; Superinfection</p><p>The use of levofloxacin, especially if prolonged, may result in overgrowth of non- susceptible organisms. If superinfection&nbsp; occurs during therapy, appropriate measures should be taken.</p><p>-&nbsp;&nbsp; Interference with laboratory test</p><p>In patients treated with levofloxacin, determination of opiates in urine may give false- positive results. It may be necessary to confirm positive opiate screens by more specific method.</p><p>Levofloxacin may inhibit the growth of Mycobacterium tuberculosis and, therefore, may give false-negative results in the bacteriological diagnosis of tuberculosis.</p><p>Epidemiologic studies report an increased risk of aortic aneurysm and dissection after intake of fluoroquinolones, particularly in the older population.</p><p>Therefore, fluoroquinolones should only be used after careful benefit-risk assessment and&nbsp; after consideration of other therapeutic options in patients with positive family history of aneurysm disease, or in patients diagnosed with pre-existing aortic aneurysm and/or aortic dissection, or in presence of other risk factors or conditions predisposing for aortic aneurysm and dissection (e.g. Marfan syndrome, vascular Ehlers-Danlos syndrome, Takayasu arteritis, giant cell arteritis, Behcet&rsquo;s disease, hypertension, known atherosclerosis).</p><p>In case of sudden abdominal, chest or back pain, patients should be advised to immediately consult a physician in an emergency department.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <ul><li>&nbsp; Effect of other medicinal products on Levonic</li></ul><p>-&nbsp; Theophylline, fenbufen or similar non-steroidal anti-inflammatory drugs</p><p>No pharmacokinetic interactions of levofloxacin were found with theophylline in a clinical study. However a pronounced lowering of the cerebral seizure threshold may occur when quinolones are given concurrently with theophylline, non-steroidal anti- inflammatory drugs, or other agents which lower the seizure threshold.</p><p>Levofloxacin concentrations were about 13% higher in the presence of fenbufen than when administered alone.</p><p>-&nbsp; Probenecid and cimetidine</p><p>Probenecid and cimetidine had a statistically significant effect on the elimination of levofloxacin. The renal clearance of levofloxacin was reduced by cimetidine (24%) and probenecid (34%). This is because both drugs are capable of blocking the renal tubular secretion of levofloxacin. However, at the tested doses in the study, the statistically significant kinetic differences are unlikely to be of clinical relevance.</p><p>Caution should be exercised when levofloxacin is coadministered with drugs that affect the tubular renal secretion such as probenecid and cimetidine, especially in renally impaired patients.</p><p>- Other relevant information</p><p>Clinical pharmacology studies have shown that the pharmacokinetics of levofloxacin were not affected to any clinically relevant extent when levofloxacin was administered together with the following drugs: calcium carbonate, digoxin, glibenclamide, ranitidine.</p><ul><li>&nbsp;Effect of Levonic on other medicinal products</li></ul><p>-&nbsp;&nbsp; Ciclosporin</p><p>The half-life of ciclosporin was increased by 33% when coadministered with levofloxacin.</p><p>-&nbsp;&nbsp; Vitamin K antagonists</p><p>Increased coagulation tests (PT/INR) and/or bleeding, which may be severe, have been reported in patients treated with levofloxacin in combination with a vitamin K antagonist (e.g. warfarin). Coagulation tests, therefore, should be monitored in patients treated with vitamin K antagonists (see section 4.4).</p><p>-&nbsp;&nbsp; Drugs known to prolong QT interval</p><p>Levofloxacin, like other fluoroquinolones, should be used with caution in patients receiving drugs known to prolong the QT interval (e.g. Class IA and III anti-arrhythmics, tricyclic antidepressants, macrolides, antipsychotics) (see section 4.4 QT interval prolongation).</p><p>-&nbsp;&nbsp; Other relevant information</p><p>In a pharmacokinetic interaction study, levofloxacin did not affect the pharmacokinetics of theophylline (which is a probe substrate for CYP1A2), indicating that levofloxacin is not a CYP1A2 inhibitor.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <ul><li>&nbsp;Pregnancy; Pregnancy Category C</li></ul><p>There are limited amount of data from the use of levofloxacin in pregnant women. Animal studies do not indicate direct or indirect harmful effects with respect to reproductive toxicity (see section 5.3). However in the absence of human data and due to that experimental data suggest a risk of damage by fluoroquinolones to the weight-bearing cartilage of the growing organism, levofloxacin must not be used in pregnant women (see sections 4.3 and 5.3).</p><ul><li>&nbsp; Breast-feeding</li></ul><p>Levonic is contraindicated in breast-feeding women. There is insufficient information on the excretion of levofloxacin in human milk ; however other fluoroquinolones are excreted in breast milk. In the absence of human data and due to that experimental data suggest a&nbsp; risk of damage by fluoroquinolones to the weight-bearing cartilage of the growing organism, levofloxacin must not be used in breast-feeding women (see sections 4.3 and 5.3).</p><ul><li>&nbsp;Fertility</li></ul><p>Levofloxacin caused no impairment of fertility or reproductive performance in rats.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Some undesirable effects (e.g. dizziness/vertigo, drowsiness, visual disturbances) may impair the patient&#39;s ability to concentrate and react, and therefore may constitute a risk in situations where these abilities are of special importance (e.g. driving a car or operating machinery).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The information given below is based on data from clinical studies in more than 8300 patients and on extensive post marketing experience.</p><p>Frequencies in this table are defined using the following convention: very common (<strong>&ge;</strong>1/10), common (<strong>&ge;</strong>1/100, &lt;1/10), uncommon (<strong>&ge;</strong>1/1000, &lt;1/100), rare (<strong>&ge;</strong>1/10000, &lt;1/1000), very rare (&lt;1/10000), not known (cannot be estimated from the available data).</p><p>Within each frequency grouping, undesirable effects are presented in order of decreasing seriousness.</p><p><strong>Infections and infestations</strong></p><p>Uncommon &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Fungal infection including Canadida infection, Pathogen resistance</p><p><strong>Blood and the lymphatic system disorders</strong></p><p>Uncommon &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Leukopenia, Eosinophilia</p><p>Rare &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Thrombocytopenia, Neutropenia</p><p>Not known &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Pancytopenia, Agranulocytosis, Haemolytic anaemia</p><p><strong>Immune system disorders</strong></p><p>Rare &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Angioedema, Hypersensitivity (see section 4.4)</p><p>Not known &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Anaphylactic shocka, Anaphylactoid shocka(see section 4.4)</p><p><strong>Metabolism and nutrition disorders</strong></p><p>Uncommon &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Anorexia</p><p>Rare &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Hypoglycemia particularly in diabetic patients (see section 4.4)</p><p>Not known &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Hyperglycaemia, Hypoglycaemic coma (see section 4.4)</p><p><strong>Psychiatric disorders</strong></p><p>Common &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Insomnia</p><p>Uncommon &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Anxiety, Confusional state, Nervousness</p><p>Rare &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Psychotic reactions (with e.g. hallucination, paranoia), Depression, &nbsp;</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Agitation, Abnormal dreams, Nightmares</p><p>Not known &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Psychotic disorders with self-endangering behaviour including suicidal</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ideation or suicide attempt (see section 4.4)</p><p><strong>Nervous system disorders</strong></p><p>Common &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Headache, Dizziness</p><p>Uncommon&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;Somnolence, Tremor, Dysgeusia</p><p>Rare &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Convulsion (see sections 4.3 and 4.4), Paraesthesia</p><p>Not known &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Peripheral sensory neuropathy (see section 4.4), Peripheral sensory</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; motor neuropathy (see section 4.4), Parosmia including anosmia,</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Dyskinesia, Extrapyramidal disorder, Ageusia, Syncope, Benign</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; intracranial hypertension</p><p><strong>Eye disorders</strong></p><p>Rare &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Visual disturbances such as blurred vision (see section 4.4)</p><p>Not known &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Transient vision loss (see section 4.4)</p><p>&nbsp;</p><p><strong>Ear and Labyrinth disorders</strong></p><p>Uncommon &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Vertigo</p><p>Rare &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Tinnitus</p><p>Not known &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Hearing loss, Hearing impaired</p><p>&nbsp;</p><p><strong>Cardiac disorders</strong></p><p>Rare &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Tachycardia, Palpitation</p><p>Not known &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Ventricular tachycardia, which may result in cardiac arrest Ventricular</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; arrhythmia and torsade de pointes (reported predominantly in</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; patients with risk factors of QT prolongation), electrocardiogram QT</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; prolonged (see sections 4.4 and 4.9)</p><p><strong>Vascular disorders</strong></p><p>Common &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Applies to IV form only: Phlebitis</p><p>Rare &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Hypotension</p><p>&nbsp;</p><p><strong>Respiratory, thoracic and mediastinal disorders</strong></p><p>Uncommon &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Dyspnoea</p><p>Not known &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Bronchospasm, Pneumonitis allergic</p><p>&nbsp;</p><p><strong>Gastrointestinal disorders</strong></p><p>Common &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Diarrhoea, Vomiting, Nausea</p><p>Uncommon &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Abdominal pain, Dyspepsia, Flatulence, Constipation</p><p>Not known &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Diarrhoea &ndash;haemorrhagic which in very rare cases may be indicative</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; of enterocolitis, including pseudomembranous colitis (see section 4.4),</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Pancreatitis</p><p><strong>Hepatobiliary disorders</strong></p><p>Common &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Hepatic enzyme increased (ALT/AST, alkaline phosphatase, GGT)</p><p>Uncommon &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Blood bilirubin increased</p><p>Not known &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Jaundice and severe liver injury, including fatal cases with acute liver</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;failure, primarily in patients with severe underlying diseases (see</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; section 4.4), Hepatitis</p><p><strong>Skin and subcutaneous tissue disorders b</strong></p><p>Uncommon &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Rash, Pruritus, Urticaria, Hyperhidrosis</p><p>Not known &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Toxic epidermal necrolysis, Stevens-Johnson syndrome, Erythema</p><p>&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;multiforme, Photosensitivity reaction (see section 4.4),</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Leukocytoclastic vasculitis, Stomatitis</p><p><strong>Musculoskeletal and connective tissue disorders b</strong></p><p>Uncommon &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Arthralgia, Myalgia</p><p>Rare &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Tendon disorders (see sections 4.3 and 4.4) including tendinitis (e.g.</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Achilles tendon), Muscular weakness which may be of special</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; importance in patients with myasthenia gravis (see section 4.4)</p><p>Not known &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Rhabdomyolysis, Tendon rupture (e.g. Achilles tendon) (see</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;sections 4.3 and 4.4), Ligament rupture, Muscle rupture,Arthritis</p><p>&nbsp;</p><p><strong>Renal and urinary disorders</strong></p><p>Uncommon &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Blood creatinine increased</p><p>Rare&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;Renal failure acute (e.g. due to interstitial nephritis)</p><p>&nbsp;</p><p><strong>General disorders and administration site conditions</strong></p><p>Common &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Applies to IV form only: Infusion site reaction (pain, reddening)&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;</p><p>Uncommon&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; Asthenia</p><p>Rare &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Pyrexia</p><p>Not known &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Pain (including pain in back, chest, and extremities</p><p>&nbsp;</p><p>&nbsp;(a) Anaphylactic and anaphylactoid reactions may sometimes occur even after the first dose.</p><p>&nbsp;(b) Mucocutaneous reactions may sometimes occur even after the first dose</p><p>Other undesirable effects which have been associated with fluoroquinolone administration include:</p><p>&middot;&nbsp; attacks of porphyria in patients with porphyria.</p><p><u>Reporting of suspected adverse reactions</u></p><p>Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via:</p><ul><li>&nbsp; Saudi Arabia</li></ul><p>The National Pharmacovigilance and Drug Safety Centre (NPC)</p><p>Fax: +(966-11) 2057662</p><p>Call NPC at +(966-11) 2038222, Exts: 2317-2356-2340.</p><p>Reporting hotline: 19999</p><p>E-mail:<u> npc.drug@sfda.gov.sa</u></p><p>Website: <u>www.sfda.gov.sa/npc</u></p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>According to toxicity studies in animals or clinical pharmacology studies performed with supra-therapeutic doses, the most important signs to be expected following acute overdose of Levonic solution for infusion are central nervous system symptoms such as confusion, dizziness, impairment of consciousness, and convulsive seizures, increases in QT interval.</p><p>CNS effects including confusional state, convulsion, hallucination, and tremor have been observed in post marketing experience.</p><p>In the event of overdose, symptomatic treatment should be implemented. ECG monitoring should be undertaken, because of the possibility of QT interval prolongation. Haemodialysis, including peritoneal dialysis and CAPD, are not effective in removing levofloxacin from the body. No specific antidote exists.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: quinolone antibacterials, fluoroquinolones.</p><ul><li>&nbsp;ATC code: J01MA12</li></ul><p>Levofloxacin is a synthetic antibacterial agent of the fluoroquinolone class and is the S (-) enantiomer of the racemic active substance ofloxacin.</p><ul><li>Mechanism of action</li></ul><p>As a fluoroquinolone antibacterial agent, levofloxacin acts on the DNA-DNA-gyrase complex and topoisomerase IV.</p><ul><li>&nbsp; PK/PD relationship</li></ul><p>The degree of the bactericidal activity of levofloxacin depends on the ratio of the maximum concentration in serum (Cmax) or the area under the curve (AUC) and the minimal inhibitory concentration (MIC).</p><ul><li>Mechanism of resistance</li></ul><p>Resistance to levofloxacin is acquired through a stepwise process by target site mutations in both type II topoisomerases, DNA gyrase and topoisomerase IV. Other resistance mechanisms such as permeation barriers (common in Pseudomonas aeruginosa) and efflux mechanisms may also affect susceptibility to levofloxacin.</p><p>Cross-resistance between levofloxacin and other fluoroquinolones is observed. Due to the mechanism of action, there is generally no cross-resistance between levofloxacin and other classes of antibacterial agents.</p><ul><li>Breakpoints</li></ul><p>The EUCAST recommended MIC breakpoints for levofloxacin, separating susceptible from intermediately susceptible organisms and intermediately susceptible from resistant organisms are presented in the below table for MIC testing (mg/L).</p><p><strong>EUCAST clinical MIC breakpoints for levofloxacin (version 2.0, 2012-01-01):</strong></p><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td><p><strong>Pathogen</strong></p></td><td><p><strong>Susceptible</strong></p></td><td><p><strong>Resistant</strong></p></td></tr><tr><td><p>Enterobacteriacae</p></td><td><p>&le;1 mg/L</p></td><td><p>&gt;2 mg/L</p></td></tr><tr><td><p>Pseudomonas spp.</p></td><td><p>&le;1 mg/L</p></td><td><p>&gt;2 mg/L</p></td></tr><tr><td><p>Acinetobacter spp.</p></td><td><p>&le;1 mg/L</p></td><td><p>&gt;2 mg/L</p></td></tr><tr><td><p>Staphylococcus spp.</p></td><td><p>&le;1 mg/L</p></td><td><p>&gt;2 mg/L</p></td></tr><tr><td><p>S.pneumoniae <sup>1</sup></p></td><td><p>&le;2 mg/L</p></td><td><p>&gt;2 mg/L</p></td></tr><tr><td><p>Streptococcus A,B,C,G</p></td><td><p>&le;1 mg/L</p></td><td><p>&gt;2 mg/L</p></td></tr><tr><td><p>H.influenzae <sup>2, 3</sup></p></td><td><p>&le;1 mg/L</p></td><td><p>&gt;1 mg/L</p></td></tr><tr><td><p>M. catarrhalis <sup>3</sup></p></td><td><p>&le;1 mg/L</p></td><td><p>&gt;1 mg/L</p></td></tr><tr><td><p>Non-species related breakpoints<sup>4</sup></p></td><td><p>&le;1 mg/L</p></td><td><p>&gt;2 mg/L</p></td></tr><tr><td colspan="3"><p>&nbsp;</p><p>(1) The breakpoints for levofloxacin relate to high dose therapy.</p><p>(2) Low-level fluoroquinolone resistance (ciprofloxacin MICs of 0.12-0.5 mg/l) may occur but there is no evidence that this resistance is of clinical importance in respiratory tract infections with H. influenzae.</p><p>(3)&nbsp; Strains with MIC values above the susceptible breakpoint are very rare or not yet reported. The identification and antimicrobial susceptibility tests on any such isolate must be repeated and if the result is confirmed the isolate must be sent to a reference laboratory. Until there is evidence regarding clinical response for confirmed isolates with MIC above the current resistant breakpoint they should be reported resistant.</p><p>(4) Breakpoints apply to an oral dose of 500 mg x 1 to 500 mg x 2 and an intravenous dose of 500 mg x 1 to 500 mg x 2</p></td></tr></tbody></table><p>The prevalence of resistance may vary geographically and with time for selected species and local information on resistance is desirable, particularly when treating severe infections. As necessary, expert advice should be sought when the local prevalence of resistance is such that the utility of the agent in at least some types of infections is questionable.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>&nbsp;</p><ul><li>Absorption</li></ul><p>Orally administered levofloxacin is rapidly and almost completely absorbed with peak plasma concentrations being obtained within 1 &ndash; 2 h. The absolute bioavailability is 99 - 100 %.</p><p>Food has little effect on the absorption of levofloxacin.</p><p>Steady state conditions are reached within 48 hours following a 500 mg once or twice daily dosage regimen.</p><ul><li>&nbsp; Distribution</li></ul><p>Approximately 30 - 40 % of levofloxacin is bound to serum protein.</p><p>The mean volume of distribution of levofloxacin is approximately 100 l after single and repeated 500 mg doses, indicating widespread distribution into body tissues.</p><ul><li>&nbsp;Penetration into tissues and body fluids:</li></ul><p>Levofloxacin has been shown to penetrate into bronchial mucosa, epithelial lining fluid, alveolar macrophages, lung tissue, skin (blister fluid), prostatic tissue and urine. However, levofloxacin has poor penetration intro cerebro-spinal fluid.</p><ul><li>Biotransformation</li></ul><p>Levofloxacin is metabolised to a very small extent, the metabolites being desmethyl- levofloxacin and levofloxacin N-oxide. These metabolites account for &lt;5 % of the dose and are excreted in urine. Levofloxacin is stereochemically stable and does not undergo chiral inversion.</p><ul><li>&nbsp; Elimination</li></ul><p>Following oral and intravenous administration of levofloxacin, it is eliminated relatively slowly from the plasma (t&frac12; : 6 - 8 h). Excretion is primarily by the renal route (&gt; 85 % of the administered dose).</p><p>The mean apparent total body clearance of levofloxacin following a 500 mg single dose was 175 +/-29.2 ml/min.</p><p>There are no major differences in the pharmacokinetics of levofloxacin following intravenous and oral administration, suggesting that the oral and intravenous routes are interchangeable.</p><ul><li>&nbsp;Linearity</li></ul><p>Levofloxacin obeys linear pharmacokinetics over a range of 50 to 1000 mg.</p><ul><li>&nbsp; Special populations</li></ul><p>- Subjects with renal insufficiency</p><p>The pharmacokinetics of levofloxacin are affected by renal impairment. With decreasing renal function renal elimination and clearance are decreased, and elimination half-lives increased as shown in the table below:</p><p><strong><u>&nbsp;Pharmacokinetics in renal insufficiency following single oral 500 mg dose&nbsp; &nbsp;</u></strong></p><table border="1" cellspacing="0" cellpadding="0" style="width:381px"><tbody><tr><td style="width:141px"><p>Clcr [ml/min]</p></td><td style="width:66px"><p>&lt; 20</p></td><td style="width:86px"><p>20 - 49</p></td><td style="width:85px"><p>50 - 80</p></td></tr><tr><td style="width:141px"><p>Cl<sub>R</sub> [ml/min]</p></td><td style="width:66px"><p>13</p></td><td style="width:86px"><p>26</p></td><td style="width:85px"><p>57</p></td></tr><tr><td style="width:141px"><p>t<sub>1/2</sub> [h]</p></td><td style="width:66px"><p>35</p></td><td style="width:86px"><p>27</p></td><td style="width:85px"><p>9</p></td></tr></tbody></table><p>&middot;&nbsp; Elderly subjects</p><p>There are no significant differences in levofloxacin pharmacokinetics between young and elderly subjects, except those associated with differences in creatinine clearance.</p><p>&middot;&nbsp; Gender differences</p><p>Separate analysis for male and female subjects showed small to marginal gender differences in levofloxacin pharmacokinetics. There is no evidence that these gender differences are of clinical relevance.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Non-clinical data reveal no special hazard for humans based on conventional studies of single dose toxicity, repeated dose toxicity, carcinogenic potential and toxicity to reproduction and development.</p><p>Levofloxacin caused no impairment of fertility or reproductive performance in rats and its only effect on foetuses was delayed maturation as a result of maternal toxicity.</p><p>Levofloxacin did not&nbsp; induce gene mutations in bacterial or mammalian&nbsp; cells but did induce chromosome aberrations in Chinese hamster lung cells in vitro. These effects can be attributed to inhibition of topoisomerase II. In vivo tests (micronucleus, sister chromatid exchange, unscheduled DNA synthesis, dominant lethal tests) did not show any genotoxic potential.</p><p>Studies in the mouse showed levofloxacin to have phototoxic activity only at very high doses. Levofloxacin did not show any genotoxic potential in a photomutagenicity assay, and it reduced tumour development in a photocarcinogenicity assay.</p><p>In common with other fluoroquinolones, levofloxacin showed effects on cartilage (blistering and cavities) in rats and dogs. These findings were more marked in young animals.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>- Sodium chloride<br />- Sodium hydroxide<br />- Hydrochloric acid<br />- Water for injection</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>This medicinal product must not be mixed with heparin or alkaline solutions (e.g. sodium bicarbonate).</p><p>This medicinal product must not be mixed with other medicinal products except those mentioned in section 6.6.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                24 months.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Store below 30&deg;C.<br />Keep the bottle in the outer carton in order to protect from light.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Polypropylene bags. Pack size: 1 bag of 50 mL</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Levonic solution for infusion should be used immediately (within 3 hours) in order to prevent any bacterial contamination. No protection from light is necessary during infusion.</p><p>This medicinal product is for single use only.</p><p>The solution should be visually inspected prior to use. It must only be used if the solution is clear, greenish-yellow solution, practically free from particles.</p><p>As for all medicines, any unused medicinal product should be disposed of accordingly and in compliance with local environmental regulations.</p><ul><li>Mixture with other solutions for infusion:</li></ul><p>Levonic solution for infusion is compatible with the following solutions for infusion:</p><p>- 0.9 % sodium chloride solution</p><p>- 5 % glucose injection</p><p>- 2.5 % glucosein Ringer solution.</p><ul><li>Combination solutions for parenteral nutrition (amino acids, glucose, electrolytes) See section 6.2 for incompatibilities.</li></ul>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Jazeera Pharmaceutical Industries
Jiser Heet, after Third Industrial Zone
Riyadh-Saudi Arabia
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                02 April 2014
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>